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Abstract
The ability to determine an infant’s likelihood of
developing autism via a relatively simple neurological
measure would constitute an important scientific
breakthrough. In their recent publication in this
journal, Bosl and colleagues claim that a measure of
EEG complexity can be used to detect, with very high
accuracy, infants at high risk for autism (HRA). On the
surface, this appears to be that very scientific
breakthrough and as such the paper has received
widespread media attention. But a close look at how
these high accuracy rates were derived tells a very
different story. This stems from a conflation between
“high risk” as a population-level property and “high
risk” as a property of an individual. We describe the
approach of Bosl et al. and examine their results with
respect to baseline prevalence rates, the inclusion of
which is necessary to distinguish infants with a
biological risk of autism from typically developing
infants with a sibling with autism. This is an important
distinction that should not be overlooked.
Please see research article: http://www.biomedcentral.
com/1741-7015/9/18 and correspondence article:
http://www.biomedcentral.com/1741-7015/9/60
Introduction
In some ways, scientists investigating early autism (ASD)
face similar problems to those investigating climate
change: by the time that we are certain of our results, it
may be too late to do anything about it. Good science,
like good medicine, should be predictive and preventa-
tive. It is not possible to diagnose autism in early
infancy because it is defined by behavioral criteria that
are not manifest until after the first or second birthday
(for example, language impairments). Given the goal of
prevention, it is necessary to study children at ages too
young for clinical presentation. This will entail the study
of infants and the development of measures that do not
rely solely on overt behavior. This is precisely the
approach taken by Bosl and colleagues [1] in their
recent publication in this journal, entitled “EEG com-
plexity as a biomarker for autism spectrum disorder
risk.”
Discussion
Due to the potential importance of this research, the
paper has received press attention from all the major
news outlets, and will likely receive more. But the design
of the study is novel and complicated and the results are
hard to interpret, even for researchers in the field.
Moreover, the findings, broadly construed, are all too
easy to misinterpret and naturally lead to the false con-
clusion that scientists have discovered a technique to
detect autism in infancy using EEG. While the authors
do not claim this, many news outlets do and the head-
line “Novel biomarker for Autism Spectrum Disorder?”
comes from this very journal. A close look at the study
gives a very clear answer: No, we have not discovered a
biomarker for ASD - not yet, at least.
The central claim of their paper is not that EEG can be
used to detect a potential biomarker for autism; it is that
EEG can be used to detect a potential biomarker for
infants at “high risk” for autism (HRA). The implications
of the study hinge on what is meant by HRA. A com-
monsense interpretation would lead one to believe that
the infants in this study were identified as HRA based on
their neurological activity. But HRA, as it is used in Bosl
et al., is a technical term that refers to the relative risk of
a given population or demographic. In this case, HRA
refers specifically to “infant siblings of child with autism”.
This population is important to study because epidemio-
logical research has found higher rates of ASD as com-
pared to the population as a whole [2-4]. This increased
risk thus improves researchers’ chances of studying a
child who will later be diagnosed with autism.
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Of course, we do not need an EEG to identify these
siblings because we already know who they are. What
we want to know is whether EEG can be used to predict
whether a specific child will develop autism. That is, we
want to move from HRA at the population level to
HRA at the individual/biological level. To this end, we
can use current prevalence (that is, risk) estimates to
predict how many children in a given sample will be
diagnosed with ASD.
The prevalence of ASD in the general population is
around 1 in 100 or 1%. The prevalence (relative risk) is
higher in siblings of a child with autism (around 5%)
and is even higher in later-born siblings. This is known
as recurrence risk and it increases to around 10% [2-4].
These later-born siblings constitute the HRA group in
Bosl et al.’s recent publication. “High risk” may be an
appropriate label if we consider that the relative risk of
this population is 10 times higher than that of the com-
parison group (CON) in this study. Put another way,
finding 10 pre-ASD infants from a random sample of
the general population would require a sample size of
around 1,000. Finding the same number using an HRA
group would only require a sample size of roughly 100,
making this a highly sought after population for autism
research.
The media-friendly finding provided by Bosl and col-
leagues was that a non-invasive neurological measure
could be used to distinguish between HRA infants and
non-HRA infants with around 80% accuracy, and some-
times higher. Accuracy for boys at nine months of age
was close to 100%. This sounds impressive. But risk, as
explained above, is a population-level property; it cannot
also be an internal property of all or even most of the
individuals in that population. Groups are not diagnosed
with autism - people are. It appears that Bosl et al. have
conflated this important distinction and a closer look at
the study reveals how this was done.
The paper, at its core, is not about autism. It is about
whether a technique for deriving the relative complex-
ities of EEG signals can be used in what is essentially a
two-category (HRA or CON) sorting task. The techni-
que creates a measure of multiscale entropy (ME). The
ME profiles are the data (dependent measures) that will
require sorting. The task of sorting was carried out by
three statistical learning techniques, the most successful
of which was a Bayesian classification algorithm. Via
supervised learning (that is, learning from its mistakes),
the program learned to correctly sort the ME data into
the two categories quite well, averaging around 80%
accuracy, and sometimes higher, as noted above.
The accuracy of the learning algorithms could be
determined because the researchers knew with 100%
accuracy which child had a sibling with ASD (HRA) and
which child did not (CON). This is also how the
learning algorithms were able to learn from their mis-
takes. The correct answers were already known. It
remains to be seen whether ME measures can tell us
about actual/biological risk for autism, but it is clear
that the learning algorithms were trained with ME data
that will not predict autism the large majority of the
time. In fact, by and large, the higher the accuracy rates
derived from these ME profiles, the less likely that those
MEs will be biomarkers for ASD.
This is best illustrated by keeping relative risk at the
population level, where it belongs. Thus, even though
ASD risk is 10 times higher for the HRA group, it is
still the case that roughly 90% of the infants in the Bosl
et al. study will not receive a diagnosis of ASD [2-4].
Given this, a report of 100% accuracy will include MEs
that will not lead to ASD in 90% of those tested; that is,
if used as diagnostic for ASD, those MEs would produce
a false positive or false alarm rate of 90%. Only when
we incorporate baseline prevalence rates (that is, the
likelihood of having the condition prior to testing) can
we determine a diagnostic test’s positive predictive value
(PPV) [5]. This can be done via Bayes’ Rule [6], which
Bosl et al. did not include. We want to know the PPV
because it tells us the proportion of individuals with a
positive test that actually has (or will have) the condi-
tion. Using the MEs that were correctly sorted 80% of
the time will result in a positive predictive value of
around .30, or 30%. A diagnostic test that promises to
be wrong most of the time would likely do more harm
than good. (The precise value will vary by condition.
Using the data from the 18-month-olds, which reported
a specificity of .8, we calculated a PPV of .307. The cal-
culation using Bayes’ Rule is as follows:
P (ASD|PositiveTest) = (P (PositiveTest|ASD)P (ASD)) /P (PositiveTest)
= (0.8 ∗ 0.1) / ((0.8 ∗ 0.1) + (0.2 ∗ 0.9)) = 0.307.
Note that this calculation assumes that the test is only
given to siblings of those diagnosed with ASD. If the
test were used in a general population, the base rate for
ASD would be much lower and the test’s utility at iden-
tifying those who might have ASD would be much
worse. For example, the PPV would be 0.04 if we
assumed a base rate of 0.01.)
Nevertheless, research with these siblings is crucial to
our understanding of the neurological underpinnings of
autism, and the data from Bosl et al. may turn out to be
groundbreaking, albeit not in its present form. In addi-
tion to the increased risk of ASD, 10 to 20% of later-
born siblings may show some autism-like symptoms (for
example, language delay) without meeting formal cri-
teria, and family members of an individual with ASD
have higher rates of psychiatric and developmental dis-
orders compared to the general population [2,3]. As
suggested by the authors, ME may index an
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endophenotype, that is, some shared factor or trait indi-
cative of specific (shared) genetic contributions to a dis-
ease or disorder. This may be the case, but twin studies
point to largely non-overlapping genetic influences on
the various features of autism [7] and an increasing
number of cases of ASD are associated with de novo
mutations [8]. Increased ME might also reflect epige-
netic effects. For instance, infant EEG activity is known
to be influenced by maternal depression [9] and mothers
of children with developmental disabilities show
increased rates of depression and anxiety [10]. Whatever
the case, abnormal brain development is the proximate
cause of ASD and Bosl et al.’s data are important
regardless of whether a specific genetic contribution is
isolable.
Conclusions
While it may not be scientifically interesting to identify
all or even most of these siblings via the same neurolo-
gical marker, we know that some of these children will
meet formal criteria for ASD and others will show
related anomalies. By tracking the development of these
children, their various outcomes can then be used to
look back at the data presented here. Once these out-
comes are known, the ME profiles of these specific chil-
dren, at various stages of development, will become the
measures of keen interest and may well represent a bio-
marker for ASD. These ME profiles could even be used
to help the learning algorithms find ME profiles that are
likely to lead to ASD or a milder impairment, or those
that are predictive of a typically developing child. This
will be very important information indeed, and such a
finding would be worthy of widespread media attention.
The discovery of such a biomarker will, however, render
the present results of the learning procedure’s accuracy
almost useless. Rather than lumping the siblings into a
single group, we want to know what is different about
them. Bosl et al. have the data that could very well tell
us what those differences are and we very much look
forward to their follow-up work. Indeed, using the base-
line prevalence rates discussed above as a constraint, a
different analysis of their current data should be able to
generate predictions as to which individuals are likely to
develop atypically and which are not, even before these
individual outcomes are known. Once we are able to
distinguish between “high risk” at the population level
from “high risk” at the biological/individual level, we
will have the kind of predictive tools best suited for the
ultimate aim of prevention.
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